30 Participants Needed

Reimbursement Strategies for Breast Cancer

CW
SI
Overseen ByStacey Ingram, MEd
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Reimbursement for breast cancer?

The research suggests that new reimbursement strategies, like episode-based payments and the Oncology Medical Home program, can improve patient outcomes by aligning financial incentives with better care practices and reducing unnecessary costs. These strategies have shown promise in enhancing care quality and reducing avoidable hospital visits, which could indirectly support better outcomes for breast cancer patients.12345

How does the treatment in the 'Reimbursement Strategies for Breast Cancer' trial differ from other breast cancer treatments?

The trial focuses on reimbursement strategies rather than a specific treatment, highlighting how financial policies can impact the delivery of care for breast cancer patients, which is different from traditional trials that focus on the medical or therapeutic aspects of treatment.23678

What is the purpose of this trial?

The goal of this clinical trial is to identify the recommended financial reimbursement amount for women with breast cancer enrolled in a clinical trial. The main questions it aims to answer are:1. What is the recommended financial reimbursement amount in trial-enrolled women with breast cancer experiencing financial toxicity?2. What do patients think about receiving a reimbursement for trial-incurred expenses?Participants will receive a monthly reimbursement to compensate for their trial-incurred expenses in cohorts, which will de-escalate for the next participant cohort if patients find the reimbursement dose suitable (negative financial toxicity screen, reimbursement dose deemed acceptable/appropriate). Researchers will also use qualitative interviews to explore patient perceptions of the trial reimbursements.

Research Team

CW

Courtney Williams, DrPH

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

This trial is for women with breast cancer who are already part of the I-SPY TRIAL 2 at UAB Medical Oncology Clinic. It's not open to men, non-English speakers, or female patients not enrolled in I-SPY TRIAL 2.

Inclusion Criteria

I am a woman with breast cancer participating in the I-SPY TRIAL 2 at UAB.

Exclusion Criteria

Non-English speakers
I am a female cancer patient not participating in the I-SPY TRIAL 2.
I am a female and I do not have cancer.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a monthly reimbursement to offset trial-related expenses

24 months
Monthly visits for reimbursement assessment

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Reimbursement
Trial Overview The study is testing different amounts of money given back to participants to cover costs related to being in a clinical trial. The goal is to find out what amount feels right and helps reduce financial stress from these expenses.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Patients receiving reimbursementExperimental Treatment1 Intervention
Monthly reimbursement to offset trial-related expenses

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

Findings from Research

The Radiation Oncology Alternative Payment Model (RO Model) indicates that brachytherapy monotherapy for prostate, uterine, and cervical cancers will receive increased reimbursements, suggesting a financial incentive for its use in treatment.
In contrast, combination therapy episodes involving both brachytherapy and external beam radiation will face reduced reimbursements, which could potentially limit access to comprehensive care for some cancer patients.
Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy Reimbursement.Thaker, NG., Meghani, R., Wilson, C., et al.[2022]

References

Value and payment for oncology in the United States. [2013]
Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. [2012]
Current issues in oncology reimbursement. [2005]
Lessons from an oncology medical home collaborative. [2019]
Episode-based payment for cancer care: a proposed pilot for Medicare. [2022]
[Standard treatment cost of female breast cancer at different TNM stages]. [2022]
Assessment of the current Medicare reimbursement system for breast cancer operations. [2007]
Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy Reimbursement. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security